Pfizer's Next-Generation Obesity Drug in Phase 2 Trials
Shows Lower Weight-Loss Efficacy Compared to Zepbound

The challenges facing latecomers entering the obesity treatment market are growing increasingly daunting. Paradoxically, the phase 2 clinical trial results for Pfizer’s ambitious obesity drug candidate have become an opportunity to reconfirm just how high a wall these late entrants are up against.


According to the industry on the 5th, Pfizer announced during its fourth-quarter 2025 conference call that its next-generation obesity treatment candidate, PF-08653944, showed a 12.3% weight-loss effect at week 28 in a phase 2b clinical trial targeting obese or overweight adults without type 2 diabetes. However, the share price fell by about 3.3% on the day of the announcement. The cool-headed assessment was that the data lacked a “decisive breakthrough” strong enough to topple the dominance of first movers Eli Lilly and Novo Nordisk. Pfizer had previously strengthened its obesity-treatment pipeline by acquiring U.S. biotech Metsera for 10 billion dollars (about 14.605 trillion won). The candidate in question was also a treatment that Metsera had been developing.


Is an "Ultra-Gap" Trend Emerging in the Obesity Drug Market? View original image

A closer look at the clinical data only deepens the concerns of latecomers. Pfizer’s main selling point was the convenience of “once-monthly dosing.” Reducing the number of injections to one quarter of Eli Lilly’s Mounjaro/Zepbound (tirzepatide), which must be injected weekly, or Novo Nordisk’s Wegovy (semaglutide), is clearly an advance. However, the market is demanding either “overwhelming efficacy” or “flawless safety,” rather than just better convenience.


The 12.3% weight-loss rate achieved by Pfizer’s candidate falls short of the roughly 16% reduction Zepbound has demonstrated over a similar period. Within the industry, the prevailing view is that physicians and patients have little incentive to switch to a new drug whose efficacy is similar to, or slightly lower than, that of the leading products, which have already been prescribed to millions of people and proven safe.


While latecomers are setting their sights on catching up to today’s Zepbound and Wegovy, the market leaders are already moving on to the next stage. Eli Lilly’s triple agonist retatrutide, now in the final stages of phase 3 trials, has shown about 24–26% weight loss at week 48, effectively heralding an efficacy level comparable to metabolic bariatric surgery. Novo Nordisk has likewise released clinical data for cagrilintide/semaglutide (CagriSema), a combination of an amylin receptor agonist and a GLP-1 (glucagon-like peptide-1) agent, showing an average weight loss of more than 22% at week 68.


Other challengers are also struggling. Amgen’s maridebart cafraglutide (Maridebart), which uses a unique antibody-drug conjugate mechanism and even raised expectations for “once-quarterly dosing,” has not fully dispelled concerns about bone-density reduction that emerged in phase 1 trials. Although Amgen has drawn a line under the issue, calling it a misinterpretation of the data, safety concerns could become an Achilles’ heel for obesity drugs, which must be taken long term. Roche’s oral candidate CT-996 also showed a respectable 6.1% weight-loss effect in early clinical trials, but gastrointestinal side effects characteristic of the GLP-1 class, such as nausea and vomiting, were reported more frequently than with injectable formulations.



Is an "Ultra-Gap" Trend Emerging in the Obesity Drug Market? View original image

An industry insider said, “Latecomers in the obesity treatment market must compete with numerous new drugs, including those from Eli Lilly and Novo Nordisk, which have already secured the lead,” adding, “Targeting niche segments by emphasizing durability and convenience is likely to become a key strategy.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing